Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$11.04 USD
-0.22 (-1.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.02 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NRIX 11.04 -0.22(-1.95%)
Will NRIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
Other News for NRIX
Insider Sell Alert: Houte Van Sells Shares of Nurix Therapeutics Inc (NRIX)
Oppenheimer Reiterates Outperform Rating for Nurix Therapeutics (NRIX) | NRIX Stock News
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX)
Nurix Therapeutics price target lowered by $2 at Oppenheimer, here's why
6 Analysts Assess Nurix Therapeutics: What You Need To Know